A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Interleukin-2 (Primary) ; Ipilimumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2018 Status changed from suspended to withdrawn prior to enrolment as the study was replaced by another study.
- 11 May 2018 Status changed from recruiting to suspended due to Pending amendment.
- 07 Feb 2018 Status changed from not yet recruiting to recruiting.